SWM
ONCT

Spire Wealth Management’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Spire Wealth Management’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-225
Closed -$10K – 2960
2021
Q4 		$10K Buy
+225
New +$15.1K ﹤0.01% 2397
2021
Q2 		– Sell
-325
Closed -$49K – 3049
2021
Q1 		$49K Buy
+325
New +$43K ﹤0.01% 1738

Other funds holding ONCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Spire Wealth Management's ONCT Position: Q1 2022 in Review

Spire Wealth Management sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2022, closing a stake of 225 shares — an estimated $10K sold.

Spire Wealth Management first reported a position in ONCT in Q1 2021 and held it in 2 quarters. The position peaked at $49K in Q1 2021. 78 funds tracked by Wall St. Rank hold ONCT as of Q1 2022.

  • Spire Wealth Management reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Spire Wealth Management sold 225 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $10K.
  • Spire Wealth Management first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q1 2021 and held it in 2 quarters.
  • Spire Wealth Management's Oncternal Therapeutics, Inc. Common Stock position peaked at $49K in Q1 2021.
  • 78 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Spire Wealth Management's 13F filing for Q1 2022, filed 18 Apr 2022.